WASHINGTON (dpa-AFX) - Novo Nordisk (NVO) said that it has resubmitted the
new drug application (NDA) for fast-acting insulin aspart as a class II
re-submission to the US Food and Drug Administration.
In October 2016, Novo Nordisk announced that...
WASHINGTON (dpa-AFX) - Novo Nordisk (NVO) said Friday that the Committee for
Medicinal Products for Human Use or CHMP, under the European Medicines Agency or
EMA, has issued a positive opinion, recommending an update of the label for
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Novo Nordisk A/S (NVO):